This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Peck K., Sher Y.P., Shih J.Y., Roffler S.R., Wu C.W., Yang P.C.: Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res.58, 2761–2765 (1998)PeckK.SherY.P.ShihJ.Y.RofflerS.R.WuC.W.YangP.C.Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients58276127651998Search in Google Scholar
Schwarzenbach H., Alix-Panabières C., Müller I., Letang N., Vendrell J.P., Rebillard X., Pantel K.: Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res.15, 1032–1038 (2009)SchwarzenbachH.Alix-PanabièresC.MüllerI.LetangN.VendrellJ.P.RebillardX.PantelK.Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer1510321038200910.1158/1078-0432.CCR-08-191019188176Search in Google Scholar
Punnoose E.A., Lackner M.R. i wsp.: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res.18, 2391–2401 (2012)PunnooseE.A.LacknerM.R.Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib1823912401201210.1158/1535-7163.TARG-11-PR-3Search in Google Scholar
Kidess-Sigal E, Jeffrey S.S i wsp.: Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget, 7, 85349–85364 (2016)Kidess-SigalEJeffreyS.SEnumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer78534985364201610.18632/oncotarget.13350535674127863403Search in Google Scholar
Higgins M.J., Park B.H i wsp.: Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res.18, 3462–3469 (2012)HigginsM.J.ParkB.HDetection of tumor PIK3CA status in metastatic breast cancer using peripheral blood1834623469201210.1158/1078-0432.CCR-11-2696353337022421194Search in Google Scholar
Zhu G., Ye X., Dong Z., Lu Y. C., Sun Y., Liu Y., McCormack R., Gu Y., Liu X.: Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. J. Mol. Diagn.17, 265–272 (2015)ZhuG.YeX.DongZ.LuY. C.SunY.LiuY.McCormackR.GuY.LiuX.Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer17265272201510.1016/j.jmoldx.2015.01.00425769900Search in Google Scholar
Thierry A.R., Ychou M. i wsp.: Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med.20, 430–435 (2014)ThierryA.R.YchouM.Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA20430435201410.1038/nm.351124658074Search in Google Scholar
Yang Y., Shen X., Li R., Shen J., Zhang H., Yu L., Liu B., Wang L.: The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. Oncotarget, 8, 49773–49782 (2017)YangY.ShenX.LiR.ShenJ.ZhangH.YuL.LiuB.WangL.The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC84977349782201710.18632/oncotarget.17937556480628572536Search in Google Scholar
Mazurek A.M., Rutkowski T., Fiszer-Kierzkowska A., Małusecka E., Składowski K.: Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol.54, 36–41 (2016)MazurekA.M.RutkowskiT.Fiszer-KierzkowskaA.MałuseckaE.SkładowskiK.Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients543641201610.1016/j.oraloncology.2015.12.00226786940Search in Google Scholar
D’Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., Westra W.H., Gillison M.L.: Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med.356, 1944–1956 (2007)D’SouzaG.KreimerA.R.ViscidiR.PawlitaM.FakhryC.KochW.M.WestraW.H.GillisonM.L.Case-control study of human papillomavirus and oropharyngeal cancer35619441956200710.1056/NEJMoa06549717494927Search in Google Scholar
Lohavanichbutr P., Chen C. i wsp.: Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch. Otolaryngol. Head Neck Surg.135, 180–188 (2009)LohavanichbutrP.ChenC.Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices135180188200910.1001/archoto.2008.540276182919221247Search in Google Scholar
Mehanna H., Beech T., Nicholson T., El-Hariry I., McConkey C., Paleri V., Roberts S.: Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head & Neck, 35, 747–755 (2013)MehannaH.BeechT.NicholsonT.El-HariryI.McConkeyC.PaleriV.RobertsS.Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region35747755201310.1002/hed.22015Search in Google Scholar
Ganguly N., Parihar S.P.: Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J. Biosci.34, 113–123 (2009)GangulyN.PariharS.P.Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis34113123200910.1007/s12038-009-0013-7Search in Google Scholar
Faridi R., Zahra A., Khan K., Idrees M.: Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol. J.8, 1–8 (2011)FaridiR.ZahraA.KhanK.IdreesM.Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer818201110.1186/1743-422X-8-269Search in Google Scholar
Mack D.H., Laimins L.A.: A keratinocyte-specific transcription factor, KRF-1, interacts with AP-1 to activate expression of human papillomavirus type 18 in squamous epithelial cells. Proc. Natl. Aca.d Sci. USA, 88, 9102–9106 (1991)MackD.H.LaiminsL.A.A keratinocyte-specific transcription factor, KRF-1, interacts with AP-1 to activate expression of human papillomavirus type 18 in squamous epithelial cells8891029106199110.1073/pnas.88.20.9102Search in Google Scholar
Yoon C.S., Kim K.D., Park S.N., Cheong S.W.: alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem. Biophys. Res. Commun.283, 668–673 (2001)YoonC.S.KimK.D.ParkS.N.CheongS.W.alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP283668673200110.1006/bbrc.2001.4838Search in Google Scholar
Walline H.M., Carey T.E. i wsp.: High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol. Head Neck Surg.139, 1320–1327 (2013)WallineH.M.CareyT.E.High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods13913201327201310.1001/jamaoto.2013.5460Search in Google Scholar
Lont A.P., Kroon B.K., Horenblas S., Gallee M.P., Berkhof J., Meijer C.J., Snijders P.J.: Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int. J. Cancer, 119, 1078–1081 (2006)LontA.P.KroonB.K.HorenblasS.GalleeM.P.BerkhofJ.MeijerC.J.SnijdersP.J.Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival11910781081200610.1002/ijc.21961Search in Google Scholar
Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J.M., Koutsky L.A.: Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA, 288, 1749–1757 (2002)KulasingamS.L.HughesJ.P.KiviatN.B.MaoC.WeissN.S.KuypersJ.M.KoutskyL.A.Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral28817491757200210.1001/jama.288.14.1749Search in Google Scholar
Lee S.A., Song Y.S. i wsp.: Multiple HPV infection in cervical cancer screened by HPVDNA Chip. Cancer Lett.198, 187–192 (2003)LeeS.A.SongY.S.Multiple HPV infection in cervical cancer screened by HPVDNA Chip198187192200310.1016/S0304-3835(03)00312-4Search in Google Scholar
Münger K., Yee C.L., Phelps W.C., Pietenpol J.A., Moses H.L., Howley P.M.: Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol.65, 3943–3948 (1991)MüngerK.YeeC.L.PhelpsW.C.PietenpolJ.A.MosesH.L.HowleyP.M.Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences6539433948199110.1128/jvi.65.7.3943-3948.1991Search in Google Scholar
Havre P.A., Yuan J., Hedrick L., Cho K.R., Glazer P.M.: p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res.55, 4420–4424 (1995)HavreP.A.YuanJ.HedrickL.ChoK.R.GlazerP.M.p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells55442044241995Search in Google Scholar
Hiller T., Poppelreuther S., Stubenrauch F., Iftner T.: Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol. Biomarkers Prev.15, 1262–1267 (2006)HillerT.PoppelreutherS.StubenrauchF.IftnerT.Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification1512621267200610.1158/1055-9965.EPI-05-0778Search in Google Scholar
Wallin K.L., Wiklund F., Angström T., Bergman F., Stendahl U., Wadell G., Hallmans G., Dillner J.: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Eng.l J. Med.341, 1633–1638 (1999)WallinK.L.WiklundF.AngströmT.BergmanF.StendahlU.WadellG.HallmansG.DillnerJ.Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer34116331638199910.1056/NEJM199911253412201Search in Google Scholar
de Visser K.E., Korets L.V., Coussens L.M.: De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell, 7, 411–423 (2005)de VisserK.E.KoretsL.V.CoussensL.M.De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent7411423200510.1016/j.ccr.2005.04.014Search in Google Scholar
Ylitalo N., Adami H.O. i wsp.: A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res.60, 6027–6032 (2000)YlitaloN.AdamiH.O.A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ60602760322000Search in Google Scholar
Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., Zur Hausen H.: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature, 314, 111–114 (1985)SchwarzE.FreeseU.K.GissmannL.MayerW.RoggenbuckB.StremlauA.Zur HausenH.Structure and transcription of human papillomavirus sequences in cervical carcinoma cells314111114198510.1038/314111a0Search in Google Scholar
Scheffner M., Werness B.A., Huibregtse J.M., Mayer W., Roggenbuck B., Stremlau A., Zur Hausen H.: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129–1136 (1990)ScheffnerM.WernessB.A.HuibregtseJ.M.MayerW.RoggenbuckB.StremlauA.Zur HausenH.The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p536311291136199010.1016/0092-8674(90)90409-8Search in Google Scholar
Dong W., Tommasino M. i wsp.: Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J. Virol.79, 14899–14908 (2005)DongW.TommasinoM.Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38791489914908200510.1128/JVI.79.23.14899-14908.2005128756616282489Search in Google Scholar
Hagensee M.E., Yaegashi N., Galloway D.A.: Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol.67, 315–322 (1993)HagenseeM.E.YaegashiN.GallowayD.A.Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins67315322199310.1128/jvi.67.1.315-322.19932373658380079Search in Google Scholar
Liu X., Clements A., Zhao K., Marmorstein R.: Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem.281, 578–586 (2006)LiuX.ClementsA.ZhaoK.MarmorsteinR.Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor281578586200610.1074/jbc.M50845520016249186Search in Google Scholar
Santer F.R., Moser B., Spoden G.A., Jansen-Dürr P., Zwerschke W.: Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation. Carcinogenesis, 28, 2511–2520 (2007)SanterF.R.MoserB.SpodenG.A.Jansen-DürrP.ZwerschkeW.Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation2825112520200710.1093/carcin/bgm19917827406Search in Google Scholar
Vogt M., Butz K., Dymalla S., Semzow J., Hoppe-Seyler F.: Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene, 25, 4009–4015 (2006)VogtM.ButzK.DymallaS.SemzowJ.Hoppe-SeylerF.Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein2540094015200610.1038/sj.onc.120942916462759Search in Google Scholar
Iovino F, Lentini L, Amato A, Di Leonardo A.: RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol. Cancer, 5, 1–11 (2006)IovinoFLentiniLAmatoADi LeonardoA.RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts5111200610.1186/1476-4598-5-38161325416987420Search in Google Scholar
Dalal S., Gao Q., Androphy E.J., Band V.: Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol.70, 683–688 (1996)DalalS.GaoQ.AndrophyE.J.BandV.Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells70683688199610.1128/jvi.70.2.683-688.19961898678551603Search in Google Scholar
Camus S., Menéndez S., Cheok C.F., Stevenson L.F., Lain S., Lane D.P.: Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene, 26, 4059–4070 (2007)CamusS.MenéndezS.CheokC.F.StevensonL.F.LainS.LaneD.P.Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E62640594070200710.1038/sj.onc.1210188274271317224909Search in Google Scholar
Jabbar S., Strati K., Shin M.K., Pitot H.C., Lambert P.F.: Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology, 407, 60–67 (2010)JabbarS.StratiK.ShinM.K.PitotH.C.LambertP.F.Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice4076067201010.1016/j.virol.2010.08.003294645920797753Search in Google Scholar
Rutkowski T., Składowski K.: Impact of human papillomavirus (HPV) on pathogenesis, treatment and prognosis of head and neck cancer. Współczesna Onkol.13, 233–240 (2009)RutkowskiT.SkładowskiK.Impact of human papillomavirus (HPV) on pathogenesis, treatment and prognosis of head and neck cancer132332402009Search in Google Scholar
Koopman L.A., Szuhai K., van Eendenburg J.D., Bezrookove V., Kenter G.G., Schuuring E., Tanke H., Fleuren G.J.: Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res.59, 5615–5624 (1999)KoopmanL.A.SzuhaiK.van EendenburgJ.D.BezrookoveV.KenterG.G.SchuuringE.TankeH.FleurenG.J.Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines59561556241999Search in Google Scholar
Ziegert C., Wentzensen N., Vinokurova S., Kisseljov F., Einenkel J., Hoeckel M., von Knebel Doeberitz M.: A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene, 22, 3977–3984 (2003)ZiegertC.WentzensenN.VinokurovaS.KisseljovF.EinenkelJ.HoeckelM.von Knebel DoeberitzM.A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques2239773984200310.1038/sj.onc.120662912813471Search in Google Scholar
Peitsaro P., Johansson B., Syrjänen S.: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J. Clin. Microbiol.40, 886–891 (2002).PeitsaroP.JohanssonB.SyrjänenS.Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique40886891200210.1128/JCM.40.3.886-891.200212027511880410Search in Google Scholar
Wagatsuma M., Hashimoto K., Matsukura T.: Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences. J. Virol.64, 813–821 (1990)WagatsumaM.HashimotoK.MatsukuraT.Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences64813821199010.1128/jvi.64.2.813-821.1990Search in Google Scholar
Lace M.J., Anson J.R., Klussmann J.P., Wang D.H., Smith E.M., Haugen T.H., Turek L.P.: Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers. J. Virol.85, 1645–1654 (2011)LaceM.J.AnsonJ.R.KlussmannJ.P.WangD.H.SmithE.M.HaugenT.H.TurekL.P.Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers8516451654201110.1128/JVI.02093-10302887521123375Search in Google Scholar
Matovina M., Sabol I., Grubisić G., Gašperov N.M., Grce M.: Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. Gynecol. Oncol.113, 120–127 (2009)MatovinaM.SabolI.GrubisićG.GašperovN.M.GrceM.Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions113120127200910.1016/j.ygyno.2008.12.00419157528Search in Google Scholar
Olthof N.C., Huebbers C.U. i wsp.: Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS One,9, e88718 (2014)OlthofN.C.HuebbersC.U.Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression9e88718201410.1371/journal.pone.0088718393333124586376Search in Google Scholar
Walline H.M., Carey T.E. i wsp.: Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck, 39, 840–852 (2017)WallineH.M.CareyT.E.Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines39840852201710.1002/hed.24729539218428236344Search in Google Scholar
Olthof N.C., Speel E.J.M. i wsp.: Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. Int. J. Cancer, 136, E207–218 (2015)OlthofN.C.SpeelE.J.M.Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines136E207218201510.1002/ijc.29112537055525082736Search in Google Scholar
Gao G., Wang J., Kasperbauer J.L., Tombers N.M., Teng F., Gou H., Zhao Y., Bao Z., Smith D.I.: Whole genome sequencing reveals complexity in both HPV sequences present and HPV integrations in HPV-positive oropharyngeal squamous cell carcinomas. BMC Cancer, 19, 1–15 (2019)GaoG.WangJ.KasperbauerJ.L.TombersN.M.TengF.GouH.ZhaoY.BaoZ.SmithD.I.Whole genome sequencing reveals complexity in both HPV sequences present and HPV integrations in HPV-positive oropharyngeal squamous cell carcinomas19115201910.1186/s12885-019-5536-1646054030975103Search in Google Scholar
Koneva L.A., Zhang Y., Virani S., Hall P.B., McHugh J.B., Chepeha D.B., Wolf G.T., Carey T.E., Rozek L.S., Sartor M.A.: HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. Mol. Cancer Res.16, 90–102 (2018)KonevaL.A.ZhangY.ViraniS.HallP.B.McHughJ.B.ChepehaD.B.WolfG.T.CareyT.E.RozekL.S.SartorM.A.HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers1690102201810.1158/1541-7786.MCR-17-0153575256828928286Search in Google Scholar
Mellin H., Dahlgren L., Munck-Wikland E., Lindholm J., Rabbani H., Kalantari M., Dalianis T.: Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int. J. Cancer, 102, 152–158 (2002)MellinH.DahlgrenL.Munck-WiklandE.LindholmJ.RabbaniH.KalantariM.DalianisT.Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer102152158200210.1002/ijc.1066912385011Search in Google Scholar
Nulton T.J., Kim N.K., DiNardo L.J., Morgan I.M., Windle B.: Patients with integrated HPV16 in head and neck cancer show poor survival. Oral Oncol.80, 52–55 (2018)NultonT.J.KimN.K.DiNardoL.J.MorganI.M.WindleB.Patients with integrated HPV16 in head and neck cancer show poor survival805255201810.1016/j.oraloncology.2018.03.015593038429706188Search in Google Scholar
Mandel P., Metais P.: Les acides nucleiques du plasma sanguin chez l’Homme. C R Seances Soc. Biol. Fil.142, 241–243 (1948)MandelP.MetaisP.Les acides nucleiques du plasma sanguin chez l’Homme1422412431948Search in Google Scholar
Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J.: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res.37, 646–650 (1977)LeonS.A.ShapiroB.SklaroffD.M.YarosM.J.Free DNA in the serum of cancer patients and the effect of therapy376466501977Search in Google Scholar
Diaz Jr L.A., Bardelli A.: Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol.32, 579–586 (2014)Diaz JrL.A.BardelliA.Liquid biopsies: genotyping circulating tumor DNA32579586201410.1200/JCO.2012.45.2011482076024449238Search in Google Scholar
Lo Y.M., Zhang J., Leung T.N., Lau T.K., Chang A.M., Hjelm N.M.: Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet.64, 218–224 (1999)LoY.M.ZhangJ.LeungT.N.LauT.K.ChangA.M.HjelmN.M.Rapid clearance of fetal DNA from maternal plasma64218224199910.1086/30220513777209915961Search in Google Scholar
Yu S.C., Lee S.W., Jiang P., Leung T.Y., Chan K.A., Chiu R.W., Lo Y.D.: High-resolution profiling of fetal DNA clearance from maternal plasma by massively paralel sequencing. Clin. Chem.59, 1228–1237 (2013)YuS.C.LeeS.W.JiangP.LeungT.Y.ChanK.A.ChiuR.W.LoY.D.High-resolution profiling of fetal DNA clearance from maternal plasma by massively paralel sequencing5912281237201310.1373/clinchem.2013.20367923603797Search in Google Scholar
Emlen W., Mannik M.: Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. Clin. Exp. Immunol.56, 185–192 (1984)EmlenW.MannikM.Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA561851921984Search in Google Scholar
Diehl F., Vogelstein B. i wsp.: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA, 102, 16368–16373 (2005)DiehlF.VogelsteinB.Detection and quantification of mutations in the plasma of patients with colorectal tumors1021636816373200510.1073/pnas.0507904102128345016258065Search in Google Scholar
Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., Knippers R.: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res.61, 1659–1665 (2001)JahrS.HentzeH.EnglischS.HardtD.FackelmayerF.O.HeschR.D.KnippersR.DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells61165916652001Search in Google Scholar
Mouliere F., Thierry A.R. i wsp.: Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Transl. Oncol.6, 319–328 (2013)MouliereF.ThierryA.R.Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load6319328201310.1593/tlo.12445366080123730412Search in Google Scholar
Sacher AG, Paweletz C, Dahlberg SE, Alden R.S., O’Connell A., Feeney N., Mach S.L., Jänne P.A., Oxnard G.R.: Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol.2, 1014–1022 (2016)SacherAGPaweletzCDahlbergSEAldenR.S.O’ConnellA.FeeneyN.MachS.L.JänneP.A.OxnardG.R.Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer210141022201610.1001/jamaoncol.2016.0173498279527055085Search in Google Scholar
Kuo Y.B., Chen J.S., Fan C.W. Li Y.S., Chan E.C.: Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin. Chim. Acta, 433, 284–289 (2014)KuoY.B.ChenJ.S.FanC.W.LiY.S.ChanE.C.Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer433284289201410.1016/j.cca.2014.03.02424685572Search in Google Scholar
Han J.Y., Choi J.J., Kim J.Y., Han Y.L., Lee G.K.: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. BMC Cancer, 16, 1–10 (2016)HanJ.Y.ChoiJ.J.KimJ.Y.HanY.L.LeeG.K.PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer16110201610.1186/s12885-016-2678-2Search in Google Scholar
Pathak A.K., Bhutani M., Kumar S., Mohan A., Guleria R.: Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin. Chem.52, 1833–1842 (2006)PathakA.K.BhutaniM.KumarS.MohanA.GuleriaR.Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool52183318422006Search in Google Scholar
Schwarzenbach H., Hoon D.S., Pantel K.: Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer, 11, 426–437 (2011)SchwarzenbachH.HoonD.S.PantelK.Cell-free nucleic acids as biomarkers in cancer patients11426437201110.1038/nrc306621562580Search in Google Scholar
van Ginkel J.H., Slieker F.J.B., de Bree R., van Es R.J., Van Cann E.M., Willems S.M.: Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature. Oral Oncol.75, 8–15 (2017)van GinkelJ.H.SliekerF.J.B.de BreeR.van EsR.J.Van CannE.M.WillemsS.M.Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature75815201710.1016/j.oraloncology.2017.10.00729224828Search in Google Scholar
Swiecicki P.L., Brennan J.R., Mierzwa M., Spector M.E., Brenner J.C.: Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers. Laryngoscope, 129, 1836–1843 (2019)SwiecickiP.L.BrennanJ.R.MierzwaM.SpectorM.E.BrennerJ.C.Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers12918361843201910.1002/lary.27725658654630570748Search in Google Scholar
Keller L., Belloum Y., Wikman H., Pantel K.: Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br. J. Cancer, 124, 345–358 (2021)KellerL.BelloumY.WikmanH.PantelK.Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond124345358202110.1038/s41416-020-01047-5785255632968207Search in Google Scholar
Jakobsen K.K., Carlander A.F., Bendtsen S.K., Garset-Zamani M., Lynggaard C.D., Grønhøj C., von Buchwald C.: Diagnostic Accuracy of HPV Detection in Patients with Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis. Viruses, 13, 1692 (2021)JakobsenK.K.CarlanderA.F.BendtsenS.K.Garset-ZamaniM.LynggaardC.D.GrønhøjC.von BuchwaldC.Diagnostic Accuracy of HPV Detection in Patients with Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis131692202110.3390/v13091692847300134578274Search in Google Scholar
Wuerdemann N., Jain R., Adams A., Speel E.J.M., Wagner S., Joosse S. A., Klussmann J.P.: Cell-Free HPV-DNA as a Biomarker for Oropharyngeal Squamous Cell Carcinoma-A Step Towards Personalized Medicine? Cancers, 12, 2997 (2020)WuerdemannN.JainR.AdamsA.SpeelE.J.M.WagnerS.JoosseS.A.KlussmannJ.P.Cell-Free HPV-DNA as a Biomarker for Oropharyngeal Squamous Cell Carcinoma-A Step Towards Personalized Medicine?122997202010.3390/cancers12102997760270233076524Search in Google Scholar
Lee J.Y., Bhide S.: Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Brit. J. Cancer, 117, 876–883 (2017)LeeJ.Y.BhideS.Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma117876883201710.1038/bjc.2017.258558999928809864Search in Google Scholar
Dermody S.M., Haring C.T., Bhambhani C., Tewari M., Brenner J.C., Swiecicki P.L.: Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA. Curr. Treat. Option On.22, 1–11 (2021)DermodyS.M.HaringC.T.BhambhaniC.TewariM.BrennerJ.C.SwiecickiP.L.Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA22111202110.1007/s11864-021-00821-8841130133559043Search in Google Scholar
Mazurek A.M., Fiszer-Kierzkowska A., Rutkowski T., Składowski K., Pierzyna M., Ścieglińska D., Woźniak G., Głowacki G., Kawczyński R., Małusecka E.: Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma. Cancer Biomark.13, 385–394 (2013)MazurekA.M.Fiszer-KierzkowskaA.RutkowskiT.SkładowskiK.PierzynaM.ŚcieglińskaD.WoźniakG.GłowackiG.KawczyńskiR.MałuseckaE.Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma13385394201310.3233/CBM-13037124440979Search in Google Scholar
Pérez-Barrios C., Nieto-Alcolado I., Torrente M., Jiménez-Sánchez C., Calvo V., Gutierrez-Sanz L., Palka M., Donoso-Navarro E., Provencio M., Romero A.: Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl. Lung Cancer Res.5, 665–672 (2016)Pérez-BarriosC.Nieto-AlcoladoI.TorrenteM.Jiménez-SánchezC.CalvoV.Gutierrez-SanzL.PalkaM.Donoso-NavarroE.ProvencioM.RomeroA.Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing5665672201610.21037/tlcr.2016.12.03523387828149760Search in Google Scholar
Capone R.B., Pai S.I., Koch W.M., Gillison M.L., Danish H.N., Westra W.H., Daniel R., Shah K.V., Sidransky D.: Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res.6, 4171–4175 (2000)CaponeR.B.PaiS.I.KochW.M.GillisonM.L.DanishH.N.WestraW.H.DanielR.ShahK.V.SidranskyD.Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma6417141752000Search in Google Scholar
Cao H, Le Q.T. i wsp.: Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. Int. J. Radiat. Oncol. Bio.l Phys.82, e351–e358 (2012)CaoHLeQ.T.Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients82e351e358201210.1016/j.ijrobp.2011.05.061325741121985946Search in Google Scholar
Mazurek A.M., Rutkowski T., Śnietura M., Pigłowski W., Suwiński R., Składowski K.: Detection of circulating HPV16 DNA as a biomarker in the blood of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck, 41, 632–641 (2019)MazurekA.M.RutkowskiT.ŚnieturaM.PigłowskiW.SuwińskiR.SkładowskiK.Detection of circulating HPV16 DNA as a biomarker in the blood of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma41632641201910.1002/hed.2536830566259Search in Google Scholar
Ahn S.M., Chan J.Y., Zhang Z., Wang H., Khan Z., Bishop J.A., Westra W., Koch W.M., Califano J.A.: Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol. Head Neck Surg.140, 846–854 (2014)AhnS.M.ChanJ.Y.ZhangZ.WangH.KhanZ.BishopJ.A.WestraW.KochW.M.CalifanoJ.A.Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer140846854201410.1001/jamaoto.2014.1338431390425078109Search in Google Scholar
Hindson C.M., Chevillet J.R., Briggs H.A., Gallichotte E.N., Ruf I.K., Hindson B.J., Vessella R.L., Tewari M.: Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods, 10, 1003–1005 (2013)HindsonC.M.ChevilletJ.R.BriggsH.A.GallichotteE.N.RufI.K.HindsonB.J.VessellaR.L.TewariM.Absolute quantification by droplet digital PCR versus analog real-time PCR1010031005201310.1038/nmeth.2633411867723995387Search in Google Scholar
Chera B.S., Gupta G.P. i wps.: Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clin. Cancer Res.25, 4682–4690 (2019)CheraB.S.GuptaG.P.Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer2546824690201910.1158/1078-0432.CCR-19-0211667976631088830Search in Google Scholar
Hanna G.J., Supplee J.G., Kuang Y., Mahmood U., Lau C.J., Haddad R.I., Jänne P.A., Paweletz C.P. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Ann. Oncol.29, 1980–1986 (2018)HannaG.J.SuppleeJ.G.KuangY.MahmoodU.LauC.J.HaddadR.I.JänneP.A.PaweletzC.P.Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer2919801986201810.1093/annonc/mdy25130010779Search in Google Scholar
Dahlstrom K.R., Li G., Hussey C.S., Mahmood U., Lau C.J., Haddad R.I., Jänne P.A., Paweletz C.P.: Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer, 121, 3455–3464 (2015)DahlstromK.R.LiG.HusseyC.S.MahmoodU.LauC.J.HaddadR.I.JänneP.A.PaweletzC.P.Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer12134553464201510.1002/cncr.29538457561226094818Search in Google Scholar
Dok R., Nuyts S.: HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers, 8, 41 (2016)DokR.NuytsS.HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies841201610.3390/cancers8040041Search in Google Scholar
Kawecki A., Nawrocki S., Golusiński W., Grzesiakowska U., Jassem J., Krajewski R., Olszewski W.: Nowotwory nabłonkowe narządów głowy i szyi. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Sierpień 2014r. http://onkologia.zalecenia.med.pl/pdf/zalecenia_PTOK_tom1_01_Nowotwory_nablonkowe_glowy_i_szyi_20140807.pdf (16.06.2020)KaweckiA.NawrockiS.GolusińskiW.GrzesiakowskaU.JassemJ.KrajewskiR.OlszewskiW.Sierpień 2014r. http://onkologia.zalecenia.med.pl/pdf/zalecenia_PTOK_tom1_01_Nowotwory_nablonkowe_glowy_i_szyi_20140807.pdf (16.06.2020)Search in Google Scholar
Hanna G.J., Lau C.J., Mahmood U., Supplee J.G., Mogili A.R., Haddad R. Jännea P.A., Paweletz C.P.: Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol.95, 120–126 (2019)HannaG.J.LauC.J.MahmoodU.SuppleeJ.G.MogiliA.R.HaddadR.JänneaP.A.PaweletzC.P.Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer95120126201910.1016/j.oraloncology.2019.06.019Search in Google Scholar
Lell M., Baum U., Greess H., Nömayr A., Nkenke E., Koester M., Lenz M., Bautz W.: Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur. J. Radiol.33, 239–247 (2000)LellM.BaumU.GreessH.NömayrA.NkenkeE.KoesterM.LenzM.BautzW.Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI33239247200010.1016/S0720-048X(99)00120-5Search in Google Scholar
Rutkowski T.W., Widłak P.: Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer. J. Transl. Med.18, 1–10 (2020)RutkowskiT.W.WidłakP.Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer18110202010.1186/s12967-020-02330-y715803332293457Search in Google Scholar